SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

The SPY is trending as market participants keenly debate the impact of escalating military operations in the Middle East, with sentiment sharply divided between expectations of a significant downturn and beliefs in a swift "buy the dip" recovery. Traders are particularly focused on potential spikes in oil prices and their inflationary consequences, while many also scrutinize the relatively muted initial market reaction amidst the broader geopolitical uncertainty.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd is trending as escalating geopolitical tensions in the Middle East and reports of the Strait of Hormuz's effective closure drive expectations of surging oil prices. The community anticipates a significant short squeeze, drawing comparisons to its previous parabolic surge during similar global conflicts, though concerns about potential dilution are also present.

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

The United States Oil Fund (USO) is trending as escalating geopolitical tensions in the Middle East, including reports of US-Israeli strikes and Iranian retaliation, create widespread concern about disruptions to crucial oil shipping lanes like the Strait of Hormuz. The community is actively debating whether a significant oil price surge is imminent due to a real supply shock or if diplomatic efforts will quickly de-escalate the situation.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as community sentiment is sharply divided over the escalating Middle East conflict, with some anticipating a significant market correction due to rising oil prices and geopolitical uncertainty, while others expect a swift rebound following reports of key Iranian leadership casualties and potential de-escalation talks.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending due to fierce community debate surrounding reported US and Israeli military operations in Iran, with proponents lauding it as a strong strategic move by Donald Trump, while detractors criticize it as a potentially destabilizing distraction from other pressing issues.

SSgA Active Trust - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

XLE is trending due to rapidly escalating Middle East tensions, including reported attacks on oil tankers and fears of Strait of Hormuz disruptions, leading the community to widely anticipate a significant oil price surge and a major rotation of capital into energy assets.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Exxon Mobil is trending amidst intense community discussion about escalating Middle East tensions, with many anticipating that potential conflict and disruptions to the Strait of Hormuz could trigger significant oil price spikes and position XOM as a critical hedge.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevron is trending as escalating Middle East tensions fuel fears of oil supply disruptions and a potential surge in crude prices, with the community actively discussing the company's strong position to benefit from these geopolitical shifts and its expanded operations in Venezuela.

RTX Corp. is an aerospace and defense company, which engages in the provision of aerospace and defense systems and services for commercial, military, and government customers. It operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD). The Collins segment manufactures and sells aero structures, avionics, interiors, mechanical systems, mission systems, and power controls. The Pratt and Whitney segment includes the design and manufacture of aircraft engines and auxiliary power systems for commercial, military, and business aircraft. The RIS segment is involved in the development of sensors, training, and cyber and software solutions. The RMD segment offers end-to-end solutions to detect, track, and engage threats. The company was founded in 1922 and is headquartered in Arlington, VA.

RTX Corp

Raytheon Technologies Corporation

Raytheon Technologies is trending as escalating global geopolitical tensions and robust U.S. defense spending proposals drive a bullish sentiment, with the community actively discussing its critical role in missile systems and substantial contract backlog.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil Corp (BATL) is trending as escalating geopolitical tensions in the Middle East drive community discussion around a potential oil price surge and a massive short squeeze. Traders are actively weighing the recent strategic asset sale that significantly reduced debt against the backdrop of potential disruptions to vital shipping routes and the broader impact on energy markets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Galecto (NASDAQ:GLTO) CEO Hans Schambye Sells 700 Shares

Galecto, Inc. (NASDAQ:GLTO - Get Free Report) CEO Hans Schambye sold 700 shares of the business's stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $21.38...

Is the Market Bullish or Bearish on Galecto Inc?

Galecto (NASDAQ:GLTO) Shares Down 13.3% - Time to Sell?

Galecto (NASDAQ:GLTO) Stock Price Down 13.3% - Here's Why...

Small Cap Stocks To Watch Today - November 11th

Spring Valley Acquisition, enGene, Canadian Solar, Galecto, RealReal, Daily Journal Corp. (S.C.), and Navitas Semiconductor are the seven Small Cap stocks to watch today, according to MarketBeat's...

Small Cap Stocks To Research - November 10th

Spring Valley Acquisition, Galecto, Movano, Papa John's International, Strive, Inflection Point Acquisition Corp. II, and Direxion Daily PLTR Bull 2X Shares are the seven Small Cap stocks to watch...

<ul class="summary-bullets"><li>Galecto announced the acquisition of Damora Therapeutics and a $285 million private raise backed by major biotech investors, including Viking Global, RA Capital, and a16z Bio + Health.</li><li>The deal adds Damora’s portfolio of mutant calreticulin–targeting antibody therapies for rare blood cancers, with early human trial data expected in 2027.</li><li>The acquisition positions Galecto to focus on next-generation treatments for myeloproliferative neoplasms, expanding its cancer pipeline alongside its ongoing AML drug program.</li></ul>Shares of Galecto surged nearly&nbsp;25% in premarket trading on Tuesday after the biotech firm announced the acquisition of Damora Therapeutics, a private company developing next-generation antibody drugs for rare blood cancers.<h2 class="st-heading-2">Galecto Bets Big On Blood Cancer Therapies</h2>The acquisition gives Galecto control of Damora’s pipeline of mutant calreticulin (mutCALR)-targeting therapies, including DMR-001, a monoclonal antibody that aims to treat two difficult-to-manage bone marrow cancers, which are essential thrombocythemia and myelofibrosis. The company said the drug could be “best in class,” with the potential to work across a broad range of disease-driving mutations.As part of the deal, Galecto raised $285 million in a private round that drew some of the biggest names in biotech investing, including Viking Global Investors, RA Capital Management, Wellington Management, Blackstone, BB Biotech, and Andreessen Horowitz’s a16z Bio + Health. The funding gives the company enough cash to operate well into 2029, with early human trial data for DMR-001 expected in 2027.<h2 class="st-heading-2">A New Chapter For Galecto</h2>Galecto CEO Hans Schambye called the deal a “pivotal milestone” that positions the company to accelerate next-generation treatments for blood cancers driven by mutCALR, which account for roughly 25% of essential thrombocythemia and 35% of myelofibrosis cases in the U.S.Incoming board member Peter Harwin, managing partner at Fairmount, said the combined financial and clinical resources will enable Galecto to advance DMR-001 from preclinical to human testing by mid-2026, with the goal of offering a safer, more convenient treatment option for patients.<h2 class="st-heading-2">Growing Its Cancer Pipeline</h2>Beyond Damora’s assets, Galecto said it’s also advancing its own drug, GB3226, for acute myeloid leukemia (AML). The compound will be featured at the American Society of Hematology’s annual meeting in December, with an FDA filing expected in early 2026 to begin human testing.<h2 class="st-heading-2">Stocktwits Users Eye Multi-Day Rally</h2>On Stocktwits, retail sentiment for Galecto was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:962/134;" src="https://news.stocktwits-cdn.com/glto_ss_jpg_87be36e195.webp" alt="glto ss.jpg" width="962" height="134"><figcaption>GLTO sentiment and message volume as of November 11 | Source: Stocktwits</figcaption></figure>One user speculated that Galecto’s stock could turn into a “multi-day runner,” hinting at continued momentum after its sharp surge.<stembedurl>https://stocktwits.com/Bcscoatings/message/635686140</stembedurl>Another user was far more bullish, predicting the stock could hit $50 next and even climb toward $150.<stembedurl>https://stocktwits.com/BearBullRunner/message/635681400</stembedurl><a href="https://stocktwits.com/symbol/GLTO">Galecto’s stock</a> has surged by more than 270% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Galecto Biotech logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Galecto Stock Surges Premarket After Damora Acquisition — Retail Bulls Predict Another Massive Rally

Galecto announced the acquisition of Damora Therapeutics and a $285 million private raise backed by major biotech investors, including Viking Global, RA Capital, and a16z Bio + Health.

Equity

Shares of biotechnology company Galecto, Inc. (GLTO) soared 632% in the pre-market session on Tuesday. The stock is on track to hit over two-year highs.Galecto is focused on developing treatments for oncological and liver diseases. Its pipeline consists of drug candidates that target cancer and fibrosis signaling pathways, including GB1211 for the treatment of liver cirrhosis, GB1211 in combination with a checkpoint inhibitor for various oncology indications, and GB3226 for multiple genetic subsets of Acute Myeloid Leukemia (AML).On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/GLTO">GLTO stock</a> rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1362/124;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_07_at_8_17_12_AM_png_631ad32651.webp" alt="GLTO's Sentiment Meter and Message Volume as of 8:17 a.m. ET on Oct. 07, 2025 | Source: Stocktwits" width="1362" height="124"><figcaption>GLTO's Sentiment Meter and Message Volume as of 8:17 a.m. ET on Oct. 07, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that this is a pump-and-dump move.<stembedurl>https://stocktwits.com/moneytra1n/message/631281671</stembedurl>Another believes that the rally could be short-lived.<stembedurl>https://stocktwits.com/come_litaliano/message/631283183</stembedurl>In August, Galecto CEO Hans Schambye announced that the company is looking forward to submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration in the first quarter of 2026 for its lead program, GB3226. Preclinical data support the therapeutic potential of the candidate as a monotherapy and in combination to address the menin-resistant population within AML, the company said.Galecto ended the second quarter with approximately $10.2 million in cash and cash equivalents. Last month, it said that it expects this amount to be sufficient to fund operating expenses and capital requirements into 2026, including the submission of the investigational new drug application for GB3226.The company also noted that it would require substantial additional capital to finance its operations, including future clinical development of its GB3226 and GB1211 programs.GLTO stock is down by 20% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/jlr-begins-phased-restart-of-operations-more-than-a-month-after-cyber-incident/ch6P7elR3WM">JLR Begins Phased Restart Of Operations More Than A Month After Cyber Incident</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

GLTO Stock Rises A Whopping 632% Pre-Market, But Retail Investors Remain Cautious

Galecto is focused on developing treatments for oncological and liver diseases.

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.

Galecto Inc

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

Current Price	$29.58
Prev Close	$29.78
Open	$28.98
Dividend Yield	0.00%
50-Day Moving Average	$26.30
Beta	2.09
Avg. Volume	30,018.15
PE Ratio	-2.44

52-Week High	$38.33
52-Week Low	$2.01
Market Capitalization	$1.78B
EPS (Annual)	-$18.53
Price to Book	5.89
Revenue Per Employee	$0.00

GLTO
Galecto Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GLTO News

GLTOGalecto Inc